Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts
Executive Summary
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.